ArticleScientific reports2025
Association of blood miR-15a, miR-146a and miR-200b levels with stages of diabetic retinopathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuropathic Pain: Mapping the miRNA Landscape.Non-coding RNA · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is a serious complication of diabetes mellitus (DM). MicroRNAs (miRNAs) play crucial roles in DR pathogenesis, but their expression patterns across different DR stages remain unclear. To investigate the expression levels of hsa-miR-200b-5p, hsa-miR-146a-5p, and hsa-miR-15a-5p in the blood of patients in different stages of diabetic retinopathy. The research involved a sample size of 92 patients who had been diagnosed with type 2 diabetes. These patients were classified into three distinct groups: 50 patients with proliferative diabetic retinopathy (PDR), 30 patients with non-proliferative diabetic retinopathy (NPDR), and 12 patients with type 2 diabetes mellitus without retinopathy (DM) as a control group. The extraction of total RNA from whole blood samples was followed by RT-qPCR analysis to assess miRNA expression levels. miR-15a showed significantly higher expression in PDR compared to NPDR (P < 0.05), but no significant differences between NPDR vs. DM or PDR vs. DM. miR-146a expression was significantly increased in PDR compared to both NPDR and DM, with no significant difference between NPDR and DM. miR-200b expression was significantly higher in PDR compared to DM but showed no significant differences between NPDR vs. DM or PDR vs. NPDR. Our findings suggest that miR-15a and miR-146a are promising minimally invasive biomarkers for tracking the progression from NPDR to PDR, and distinguishing between these two stages. While elevated levels of miR-200b in PDR indicate potential utility in identifying at-risk patients. These insights may guide early therapeutic interventions and better diabetic retinopathy management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.